jhpratt@alphavestcapital.com is my email.Please email me insights into eigr.
alphavestcapital.com
MOST IMPORTANT SUMMARY SENTENCES IN THE LANCET ARTICLE:(paraphrased: EIGR’s interferon works better than monoclonal antibodies at reducing covid viral load.Plus, EIGR’s interferon can be administered on an outpatient basis. )"Added value of this study This study shows that a single subcutaneous injection of 180 µg peginterferon lambda has an antiviral effect in outpatients with COVID-19. The decline in viral load was greater with peginterferon lambda treatment than with placebo. The more rapid viral load decline and higher clearance rate were most pronounced in those with high viral loads, a finding also reported with monoclonal antibody therapies in patients with COVID-19. However, the magnitude of the viral load decline compared with that of placebo was much greater with peginterferon lambda than has been reported with monoclonal antibody therapies to date. Peginterferon lambda was safe and well tolerated in outpatients with mild-to-moderate COVID-19, with a similar side-effect profile to that of placebo and no concerning laboratory adverse events. Implications of all the available evidence No approved therapy exists for outpatients with COVID-19. This study showed that peginterferon lambda accelerated viral clearance, particularly in those with high baseline viral loads, highlighting the importance of quantitative viral load testing in the assessment of antiviral agents for patients with COVID-19. Treatment early in the course of disease might prevent clinical deterioration and shorten the duration of viral shedding, which might have an important public health effect by reducing transmission and reducing the duration of self-isolation."
